Inside the research

Boston Scientific Corporation

BSX Research profile · latest available data

Price overview

$43.92

▼ -0.76 (-1.7%)

52w hi$104.98
52w lo$42.63
Vol15.21M
As of25 Sep 2026

The Verdict

Hold

Our score -0.18

Short-0.51
Medium-0.09
Long+0.30

computed 2026-09-27

Key fundamentals

Boston Scientific Corporation

Healthcare · Medical Devices

Market cap$63.65B
Enterprise value$75.98B
Trailing P/E17.78x
Forward P/E12.87x
EV / EBITDA13.30x
P / S (ttm)3.03x
Profit margin17.5%
Return on equity15.3%
Revenue growth+7.5%
Earnings growth+15.1%
Debt / equity50.15

Layer Breakdown

LayerRawContribution
Fundamental+0.31
Sector+0.08
Technical-0.34
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

United States · www.bostonscientific.com

Risk Metrics

Beta vs SPX0.57
Corr SPX0.29
Annual vol31.6%
Annual ret-27.2%
Sharpe-0.86
Max DD-60.6%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$85.19
High / Low$110.00 / $60.00
Median$84.50
Analysts32
Strong Buy8
Buy23
Hold2
Sell0
Strong Sell0

Recent rating actions

2026-04-23Wells Fargo→ Overweight
2026-04-23Truist Securities→ Buy
2026-04-23RBC Capital→ Outperform
2026-04-23Needham→ Buy
2026-04-23Goldman Sachs→ Buy
2026-04-23Evercore ISI Group→ Outperform

Material Events

DateEvent8-K
2026-07-29Earnings Release, Exhibitsread
2026-07-27Restructuringread
2026-05-18Other Material Event, Exhibitsread
2026-05-18Other Material Event, Exhibitsread
2026-05-05Bylaws Amendment, Shareholder Vote…read
2026-04-22Earnings Release, Exhibitsread
2026-03-30Other Material Event, Exhibitsread
2026-02-26Material Agreement, Termination of Agreement…read
2026-02-23Officer / Director Change, Reg FD Disclosure…read
2026-02-05Officer / Director Changeread
2026-02-04Earnings Release, Exhibitsread
2026-01-15Material Agreement, Exhibitsread

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders9
Top-5 share94.8%
HHI2,912 (concentrated)

Top Holders

HolderValueShares
State Street Corp$2.99B70.11M
Fidelity / FMR LLC$1.95B45.70M
Capital Research / Capital World$711.51M16.67M
Citadel Advisors$433.43M10.16M
AQR Capital Management$413.22M9.68M
Millennium Management$232.13M5.94M
Renaissance Technologies$102.94M2.41M
Bridgewater Associates$18.87M442.04K
T. Rowe Price Group$301.77K7.07M

As of 2026-06-30

Federal Contracts

AmountAgencyDescription
$4.68MDepartment of DefenseTHERASPHERE
$4.04MDepartment of Veterans AffairsY90 GLASS MICROSPHERES
$2.92MDepartment of Veterans AffairsTHERASPHERE Y-90 GLASS MICROSPHERE MEDICATION
$1.38MDepartment of Veterans AffairsYTTRIUM-90 THERASPHERES
$1.36MDepartment of Veterans AffairsY90 THERASPHERE
$1.36MDepartment of Veterans AffairsCARDIAC HOLSTER MONITORING SERVICES
$1.10MDepartment of Health and Human ServicesPOTASSIUM IODINE TABS
$1.04MDepartment of Veterans AffairsY90 THERESPHERE

SEC Filings

DateFormDoc
2026-08-124view
2026-08-114view
2026-08-074view
2026-08-054view
2026-08-054view
2026-08-034view
2026-08-034view
2026-08-0310-Qview
2026-07-298-Kview
2026-07-278-Kview
2026-07-024view
2026-06-2411-Kview
2026-06-014view
2026-05-214view
2026-05-214view

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$16.75B+4.6%
Gross profit$11.49B+4.6%
Operating income$2.60B+72.7%
Cash from ops$3.44B+9.2%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$44.68$44.84$43.33$43.9215.21M
Sep 24$44.65$45.16$44.46$44.6817.30M
Sep 23$45.00$45.74$43.99$44.6218.56M
Sep 22$44.70$45.08$44.04$44.9221.07M
Sep 21$42.98$43.81$42.72$43.7225.00M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →